Menu
We are on a mission to transform lives with pioneering drugs specially designed to address various unmet needs that cause sight-threatening problems for patients around the world. We believe our science will fundamentally reshape the lives of millions of people, across the spectrum of human life. Founded with a singular vision in 2015, Theialife started out as a collaboration between Dr. Klaus Trier, MD Ophthalmologist in Copenhagen, Denmark & Bioplus Life Sciences, in India. The collaboration was to develop the molecule 7-Methyl-Xanthine for the treatment of Myopia in Children. However, our journey truly began in 1985 when Dr. Klaus started his research into connective tissues. This became the premise for his groundbreaking research into myopia in children (previously considered untreatable). Through his perseverance, a disruptive opportunity was realized in myopia. This was done by understanding the biomechanical process of myopia progression & targeting the critical component of eye elongation that leads to myopia. That key component — collagen — was discovered to be addressable by targeting the A2A receptors in the eye with ND10. This helps increase collagen deposition, thereby preventing eye elongation and inhibiting myopia progression.
ND10 is a phase-3 ready asset that has successfully completed (a) preclinical development (b) a phase-2 clinical trial in Denmark and is currently in the process of initiating a dual global phase-3 clinical trial. For over 12 years, our product has been clinically used to treat myopia progression and its associated factors in over ~1200 Danish children. The first-in-class molecule will change Myopia management, especially for children with early-onset Myopia who otherwise would progress to severe and sight-threatening Myopia given the limited therapies available. Theialife owns all IP related to the dosage form and relevant data.
Today, Theialife is a clinical-stage ophthalmology drug discovery platform that targets late-stage development candidates focused on ophthalmology-related diseases. With ND10 setting the foundation of Theialife’s mission, Theialife is developing new therapeutic options that could effectively address Myopia, as well as other eye-related diseases. We have grown our portfolio to offer a range of innovative molecules in 7 pre-clinical & clinical programs that address ocular diseases like corneal blindness, keratoconus, dry-eye disease, pterygium, & many more. Through cutting-edge eye care solutions, we aim to lead the industry. Our aspiration is to build a global disruptive ophthalmology company that embraces new opportunities to fundamentally reshape the lives of patients with serious retinal diseases.
We are committed to finding innovative therapeutic solutions based on the discovery of novel molecules (used or discovered for the first time) and pathways, which aim to address unmet medical needs that were previously viewed as untreatable, under the guidance of internationally renowned ophthalmology specialists.
Each step of the process, from idea to market, is managed internally by our experts. Innovation experts at our company are driven to go further and think bigger in their pursuit of research, development, and medical breakthroughs. In this way, we can deliver enhanced value through innovative products.
In developing countries, most patients suffering from eye diseases have no access to eye drop treatments, so they do not receive any treatment at all. Thus, we put our expertise at the service of those who need it most, either through international humanitarian missions or by supporting local initiatives. Together, we can achieve greater success by providing solutions for those who did not have the option earlier.
We are on a journey to ensure no patient is left behind. Our dependence on eyesight grows every day, and our aim is to alleviate the suffering and level the playing field for patients suffering from ophthalmic diseases without compromising our quality standards. It is also our responsibility to provide quality, sustainable employment, and career opportunities to all.
